MARKET

TRIL

TRIL

TRILLIUM THERAPE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3872
+0.0172
+4.65%
Closed 16:00 09/16 EDT
OPEN
0.3696
PREV CLOSE
0.3700
HIGH
0.3924
LOW
0.3696
VOLUME
171.14K
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
0.2440
MARKET CAP
14.19M
P/E (TTM)
-0.2103
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TRIL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TRIL News

  • H.C. Wainwright Downgrades Trillium Therapeutics to Neutral
  • Benzinga.08/19 11:38
  • The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings
  • Benzinga.08/15 11:45
  • The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
  • Benzinga.08/14 11:50
  • Trillium Therapeutics Reports Second Quarter 2019 Financial Results
  • GlobeNewswire.08/13 12:00

More

Industry

Biotechnology & Medical Research
+0.91%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Name
Price
%Change

About TRIL

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
More

Webull offers Trillium Therapeutics Inc (TRIL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.